{"title":"辉瑞成为BIND Therapeutics的第二个主要纳米医学合作伙伴","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1924","DOIUrl":null,"url":null,"abstract":"BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner. The company has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering® platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. BIND formed a similar collaboration with Amgen in January 2013 and will use the payments it receives from the two partnerships to fund a Phase II clinical programme for its lead drug candidate BIND-014 in multiple solid tumours.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"200 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I4.1924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner. The company has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering® platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. BIND formed a similar collaboration with Amgen in January 2013 and will use the payments it receives from the two partnerships to fund a Phase II clinical programme for its lead drug candidate BIND-014 in multiple solid tumours.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"200 2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I4.1924\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator
BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner. The company has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering® platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. BIND formed a similar collaboration with Amgen in January 2013 and will use the payments it receives from the two partnerships to fund a Phase II clinical programme for its lead drug candidate BIND-014 in multiple solid tumours.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
